RxDoctor Payments Data

Robert Cotes, MD

Psychiatry · Lebanon, NHNPI 1275751554

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $61,106 of the $63,930 with a category attached, or 95.6%. Aurobindo Pharma USA, Inc. accounts for 65.4% of it on its own, with 3 other manufacturers making up the rest. Among psychiatry clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$63,930in general payments, 2019–2025

Across 60 payments — averaging $1065.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurobindo Pharma USA, Inc.$42K
  • Boehringer Ingelheim$13K
  • Mylan Inc.$9K
  • Dr.reddy's Laboratories,inc.$17
$841,776in research payments, 2019–2025

Across 262 payments — averaging $3212.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alkermes, Inc.$340K
  • Hoffmann-la Roche Limited$207K
  • E.r. Squibb & Sons, L.L.C.$160K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$49K
  • H. Lundbeck A S$36K
  • Boehringer Ingelheim International GmbH$31K
  • plus $19K from 1 others

What the payments were for

  • Consulting fees$61,10696%
  • Travel & lodging$2,0023%
  • Food & beverage$8221%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,930 in reported general payments places this provider in the 95th percentile of 166 psychiatry providers in New Hampshire.

See all psychiatry providers in New Hampshire

Medicare billing

Part B allowed, 2024
$3,834
Medicare patients
15
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clozapine148$13,992
Aripiprazole21$1,025
Quetiapine Fumarate22$825
Glycopyrrolate20$712
Haloperidol25$584
Atropine Sulfate11$417
Metoprolol Succinate20$362
Bupropion XlBupropion Hcl13$351
Escitalopram Oxalate32$238
Lorazepam18$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aurobindo Pharma USA, Inc.Clozapine$41,817$13,992148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 psychiatry providers in New Hampshire.

Other psychiatry in Lebanon

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →